超燃紅橙錠
超燃紅橙錠 : Product registered in Taiwan. This registration does not constitute authorisation for sale in France or the European Union. It does not demonstrate the safety or efficacy of the product.
TFDA, Taiwan tablets, capsules and medical nutrition registers, retrieved 27 October 2026.
Taiwan Food and Drug Administration (TFDA), Open Government Data License, version 1.0
The foreign register category does not determine the regulatory category of the product in France.
French and European references for recognised ingredients
No point flagged by the rules applied to recognised ingredients.
Unidentified ingredients are not assessed. The absence of a signal does not establish product compliance.
Published composition
| Published ingredient | Published text and quantity | Identified nutrient or substance |
|---|---|---|
| ISOMALT | ISOMALT | Not identified |
| MALTODEXTRIN | MALTODEXTRIN | Maltodextrine |
| RED ORANGE EXTRACT | RED ORANGE EXTRACT | Not identified |
| L-CARNITINE | L-CARNITINE | L-carnitine |
| AFRICA MANGO EXTRACT | AFRICA MANGO EXTRACT | Not identified |
| CHITOSAN | CHITOSAN | Chitosan |
| GARCINIA EXTRACT | GARCINIA EXTRACT | Not identified |
| CORN STARCH | CORN STARCH | Not identified |
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | Not identified |
| KETONES | KETONES | Cétones |
| AROMATIC ALCOHOLS | AROMATIC ALCOHOLS | Not identified |
| ESTERS | ESTERS | Not identified |
| DEXTRIN | DEXTRIN | Not identified |
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | Not identified |
| DEXTROSE MONOHYDRATE | DEXTROSE MONOHYDRATE | Not identified |
| AROMATIC ALDEHYDES | AROMATIC ALDEHYDES | Not identified |
| SILICON DIOXIDE | SILICON DIOXIDE | Not identified |
| BLACK VINEGAR POWDER | BLACK VINEGAR POWDER | Not identified |
| CONCENTRATED BLACK VINEGAR | CONCENTRATED BLACK VINEGAR | Not identified |
| PURPLE TEA EXTRACT | PURPLE TEA EXTRACT | Not identified |
| CITRIC ACID | CITRIC ACID | Acide citrique |
| POTATO STARCH | POTATO STARCH | Not identified |
| SHEKWASHA JUICE | SHEKWASHA JUICE | Not identified |
| SUCRALOSE | SUCRALOSE | Not identified |
The imported data provide no usable daily dosage. No daily dose is estimated and no comparison with dose limits is performed. A published quantity may refer to a preparation or an unspecified unit. Chinese names are retained without translation.
Product record
- Registration number
- 1110708618
- Chinese name
- 超燃紅橙錠
- English name
- ZENSO KURO OIRU
- Type
- Imported tablets and capsules
- Published status
- Status not provided in this export; the validity date is shown separately
- Licence holder
- 唯樂生物科技股份有限公司
- Registration date
- 2022-06-01
- Published validity end
- 2027-06-01
Original register data
View published fields and their variants
- Product name
- 超燃紅橙錠
- Active ingredients
- ISOMALT;;MALTODEXTRIN;;RED ORANGE EXTRACT;;L-CARNITINE;;AFRICA MANGO EXTRACT;;MALTODEXTRIN;;CHITOSAN;;GARCINIA EXTRACT;;CORN STARCH;;PROPYLENE GLYCOL;;KETONES;;AROMATIC ALCOHOLS;;ESTERS;;DEXTRIN;;MAGNESIUM STEARATE;;DEXTROSE MONOHYDRATE;;AROMATIC ALCOHOLS;;AROMATIC ALDEHYDES;;ESTERS;;KETONES;;SILICON DIOXIDE;;BLACK VINEGAR POWDER;;CONCENTRATED BLACK VINEGAR;;PURPLE TEA EXTRACT;;MALTODEXTRIN;;CITRIC ACID;;DEXTRIN;;POTATO STARCH;;SHEKWASHA JUICE;;SUCRALOSE;;
- Valid until
- 1160601
- Registration number
- 1110708618
- Licence holder
- 唯樂生物科技股份有限公司
- Registration date
- 1110601
- Published reference
- DHC0B107086180
- Published English name
- ZENSO KURO OIRU
Official source
View the official register, number 1110708618
Taiwan Food and Drug Administration (TFDA), Open Government Data License, version 1.0
Open Government Data License, version 1.0
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- L-CARNITINE
Read the warning, when it applies and the studies cited
L-CARNITINE
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (CPS 2008).
Sources cited by Health Canada (1)
- CPS 2008: Compendium of Pharmaceuticals and Specialties: The Canadian Drug Reference for Health Professionals. Ottawa (ON): Canadian Pharmacists Association; 2008.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a seizure disorder (CPS 2008).
Sources cited by Health Canada (1)
- CPS 2008: Compendium of Pharmaceuticals and Specialties: The Canadian Drug Reference for Health Professionals. Ottawa (ON): Canadian Pharmacists Association; 2008.
- CHITOSAN
Read the warning, when it applies and the studies cited
CHITOSAN
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Pittler et al. 1999).
Sources cited by Health Canada (1)
- Pittler MH, Abbot NC, Harkness EF, Ernst E. Randomized, double-blind trial of chitosan for body weight reduction. European Journal of Clinical Nutrition 1999;53(5):379-381. PubMed Randomised trial
Condition of application: All products (except for weight management).
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
Condition of application: Weight management.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding.
Contraindications
Condition of application: All products.
Do not use if you have an allergy to seafood.
Condition of application: Weight management.
Do not use if you are pregnant (HC 2010).
Sources cited by Health Canada (2)
- HC 2010: Health Canada: Prenatal Nutrition Guidelines for health Professionals: Gestational weight gain [Accessed 2024 April 7]. Available from: https://www.canada.ca/content/dam/hc-sc/migration/hc-sc/fn-an/alt_formats/pdf/nutrition/prenatal/ewba-mbsa-eng.pdf
- SC 2010 : Santé Canada : Lignes directrices sur la nutrition pendant la grossesse à l'intention des professionnels de la santé : Gain de poids pendant la grossesse. [Consulté le 7 avril 2024]. Disponible à : https://www.canada.ca/content/dam/hc-sc/migration/hc-sc/fn-an/alt_formats/pdf/nutrition/prenatal/ewba-mbsa-fra.pdf
Known adverse reactions
When using this product you may experience gastrointestinal discomfort/disturbances (Moraru et al. 2018; Mhurchu et al. 2004; Pittler et al. 1999).
Sources cited by Health Canada (3)
- Mhurchu CN, Poppitt SD, McGill AT, Leahy FE, Bennett DA, Lin RB, Ormrod D, Ward L,Strik C, Rodgers A. (on behalf of the Effect of Chitosan on Health and Obesity (ECHO) Collaboration). The effect of the dietary supplement, Chitosan, on body weight: a randomised controlled trial in 250 overweight and obese adults. International Journal of Obesity 2004;28:1149-1156. PubMed Randomised trial
- Moraru C, Mincea MM, Frandes M, Timar B, Ostafe V. A Meta-Analysis on Randomised Controlled Clinical Trials Evaluating the Effect of the Dietary Supplement Chitosan on Weight Loss, Lipid Parameters and Blood Pressure. Medicina (Kaunas) 2018; 54(6):109. PubMed Meta-analysis
- Pittler MH, Abbot NC, Harkness EF, Ernst E. Randomized, double-blind trial of chitosan for body weight reduction. European Journal of Clinical Nutrition 1999;53(5):379-381. PubMed Randomised trial
They concern the ingredient, not this product or its dose. They do not replace medical advice.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “超燃紅橙錠”, https://compoatlas.com/en/supplements/taiwan/1110708618-zenso-kuro-oiru, updated 27 October 2026.